Influenza and other respiratory viruses · 2024
Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS-CoV-2.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Richier Quentin, De Valence Benjamin, Chopin Dorothée, Gras Emmanuelle, Levi Laura I, Abi Aad Yasmine, Pacanowski Jérôme, Meynard Jean-Luc, Plaçais Léo, Fey Dorothée, Couture Priscille, Martin-Blondel Guillaume, Pestre Vincent, Woessner Juliette, Ancellin Sophie, Weyrich Pierre, Carpentier Benjamin, Idri Salim, Tiberghien Pierre, Surgers Laure, Hueso Thomas, Lacombe Karine
Аннотация
The emergence of SARS-CoV-2 Omicron variant has led to a complete reconfiguration of the therapeutic landscape, with all monoclonal antibodies having lost any neutralization activity. We report here a case series of 75 immunocompromised patients infected by the Omicron variant who benefited from COVID-19 convalescent plasma (CCP). At Day 28, the overall survival was 76% (95% CI 67-86) with no significant difference in the clinical outcome between patients with hematological malignancies, solid organ transplantation or autoimmune diseases. No safety concern was reported during the course of the study. These results showed that CCP is well tolerated and represents a treatment option for immunocompromised patients who remain highly impacted by the COVID19 epidemic.